/ /

Cheryl Guttman Krader
Study characterizes safety of pediatric psoriasis treatments
A retrospective review of pediatric patients treated for psoriasis with systemic agents provides much needed insight about the safety and tolerability of these medications.
TFOS DEWS II report introduces new patient classification scheme
J. Daniel Nelson, MD, chair of The Tear Film and Ocular Surface Society Dry Eye Workshop II, highlights a new scheme for patient classification.
Ziv-aflibercept for DME provides BCVA gains, lower dosing burden
Results of a 1-year randomized controlled trial investigating treatment for diabetic macular edema (DME) show that intravitreal ziv-aflibercept (Zaltrap, Sanofi Genzyme) 1.25 or 2.5 mg is safe, according to Masoud Soheilian, MD.
IRIS Registry gives glimpse into DME in real world
An analysis of data collected in the Intelligent Research in Sight (IRIS) Registry suggests that in the real-world setting, newly diagnosed diabetic macular edema (DME) is being vastly undertreated. Not only are the majority of these patients not receiving active intervention, but those who are started on anti-vascular endothelial growth factor (VEGF) therapy seem to be getting a suboptimal number of injections, said Jeffrey R. Willis, MD, PhD.
Punctal plug drug delivery attractive method for managing glaucoma
Punctal plug-based delivery systems for sustained delivery of glaucoma medications represent new and versatile technology that is under development. The hope is it can help with the problem of patient compliance when managing mild-moderate glaucoma, said Marlene Moster, MD.
OCTA providing two-for-one imaging and practical value
OCT angiography (OCTA) is a revolutionary new tool that adds value to clinical practice. It provides unique insights about retinal and choroidal vasculature compared with conventional OCT along with the advantages of conventional dye-based techniques, said Philip J. Rosenfeld, MD, PhD, at the 2017 Retina Subspecialty Day meeting.
NLP status after open-globe injury not always permanent
Management of patients with loss of light perception after open-globe injury has historically been to observe or enucleate the eye with the goal of reducing the risk of sympathetic ophthalmia. Existing data, however, support rethinking that paradigm and instead considering surgery for carefully selected patients who have a chance for recovering vision.
Schepens lecturer traces advent, evolution of ophthalmic trials
Clinical trials are an indispensable ordeal that are the gold standard for assessing risks and benefits of treatments, said Frederick L. Ferris III, MD.